Skip to main content
OpenTrials
Completed

NCT Number: NCT03740776

The Eosinophils Percentage Predicts In-hospital Major Adverse Cardiac Events in STEMI Patients After PCI

Eosinophils (EOS) in peripheral blood are significantly decreased in ST-segment elevation myocardial infarction (STEMI) and the reduced EOS indicates severe myocardial damage. Whether EOS is a good predictor for in-hospital major adverse cardiac events (MACEs) of patients with ST-segment elevation myocardial infarction remains unknown. The aims of this study was to evaluate prognostic role of EOS for in-hospital MACEs in STEMI patients who have undergone primary percutaneous coronary intervention (PCI)

Completed

Looking for future studies?

Notify Me

Key information

Conditions

ST Elevation Myocardial Infarction Cardiovascular Diseases Heart Diseases Infarction Ischemia Myocardial Infarction Myocardial Ischemia Necrosis Pathologic Processes Pathological Conditions, Signs and Symptoms Vascular Diseases

Age range

20 year–85 year

Sex eligibility

All sexes

Study type

Observational

About this study

The investigators retrospectively analyzed the clinical data of 518 patients with STEMI after PCI. MACEs were defined as cardiac arrest, cardiac rapture, malignant arrhythmia and cardiac death. The receiver operating characteristic (ROC) curves were used to demonstrate the prognostic value of EOS% in in-hospital MACEs. All patients were divided into 2 groups according to the best cut-off EOS% value, including reduced EOS% group and control group. Cox regression analyses and KM survival curve were used to calculate the correlated between EOS with in-hospital MACEs.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with STEMI who underwent PCI within 12 hours from symptom onset
  • Patients from whom informed consent has been properly obtained in writing prior to start of the trial.

Exclusion criteria

  • Patients with previous myocardial infarction, congenital heart disease
  • Patients with liver disease, and renal failure
  • Patients with immunologic disease, malignant tumors, pregnancy, infection caused by various pathogens, chronic inflammatory disease, trauma.

Treatment and study plan

Primary outcomes

  1. major adverse cardiac events

    Time frame: The median time of 7 days

    the relationship between reduced eosinophils percentage and in-hospital MACE

Sponsors and collaborators

Lead sponsor

Dongying Zhang

Other

Registry information

Official study title

The Eosinophils Percentage Predicts In-hospital Major Adverse Cardiac Events in Patients With ST-elevation Myocardial Infarction After Primary Percutaneous Coronary Intervention

Important dates

Study start
2015
Primary completion
2017
Study completion
2018
First posted
Nov 14, 2018
Registry last updated
Nov 14, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.